Table 22

Results for General QoL Scales from Studies Comparing Epoetin or Darbepoetin to Placebo or No Treatment

StudyStudy armTime (wks)N randomizedN evaluable for QoL% not evaluableBlinded?QoL measure% change1p-value2
MEAN/MEDIAN BASELINE Hb < 10 g/dl
Bamias 2003 Ctl≤24722763NoEORTC QLQ-C30Not given
Epo723256Not givenNS
Boogaerts 2003 Ctl1212910916NoSF-36 PCSNot given
Epo133104229<0.05
Dammacco 2001 Ctl1276725YesNHP (each of 6 domains)Not given
Epo69664Not givenNS
Littlewood 2001 Ctl4–241249027YesSF-36 PCS−1
Epo2512002050.0512, NS
Littlewood 2001 Ctl4–241249027SF-36 MCS−1
Epo2512002050.0952, NS
Witzig 2005Ctl1617014714YesSDS3
Epo1741511310.39, NS
MEAN/MEDIAN BASELINE Hb 10 to 12 g/dl
No trials
MEAN/MEDIAN BASELINE Hb >12 g/dl
Del Mastro 1997 Ctl26312616NoPDI3
Epo31271300.4, NS
MEAN/MEDIAN BASELINE Hb UNCLEAR
Razzouk 2004A Ctl161118623YesPatient reported PedQL-I total score8
Epo111941510NS
1

% change calculated as (end-baseline)/baseline; positive values indicate improved quality of life.

2

comparing %change in treatment arm to %change in control arm.

EORTC QLQ-C3, European Organization for Research & Treatment of Cancer quality of life questionnaire; SF-36 PCS & MCS, Medical Outcomes Study, Short Form 36, Physical/Mental Component Score; NHP, Nottingham Health profile; SDS, Symptom Distress Scale; PDI, Psychological Distress Inventory; PedQL-I, Pediatrics Quality of Life Inventory; Hb, hemoglobin; Con, control; Epo, epoetin; QoL, quality of life; wks, weeks; NS, not significant; N, number of patients

From: 3, Results

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.